Abstract:Background: Non-alcoholic fatty liver disease (NAFLD) and heart failure (HF) are related conditions with an increasing incidence. However, the mechanism underlying their association remains unclear. This study aimed to explore the shared pathogenic mechanisms and common biomarkers of NAFLD and HF through bioinformatics analyses and experimental validation. Methods: NAFLD and HF-related transcriptome data were extracted from the Gene Expression Omnibus (GEO) database (GSE126848 and GSE26887). Differential analysis was performed to identify common differentially expressed genes (co-DEGs) between NAFLD and HF. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) were conducted to explore the functions and regulatory pathways of co-DEGs. Protein-protein interaction (PPI) network and support vector machine-recursive feature elimination (SVM-RFE) methods were used to screen common key DEGs. The diagnostic value of common key DEGs was assessed by receiver operating characteristic (ROC) curve and validated with external datasets (GSE89632 and GSE57345). Finally, the expression of biomarkers was validated in mouse models. Results: A total of 161 co-DEGs were screened out in NAFLD and HF patients. GO, KEGG, and GSEA analyses indicated that these co-DEGs were mainly enriched in immune-related pathways. PPI network revealed 14 key DEGs, and SVM-RFE model eventually identified two genes (CD163 and CCR1) as common key DEGs for NAFLD and HF. Expression analysis revealed that the expression levels of CD163 and CCR1 were significantly down-regulated in HF and NAFLD patients. ROC curve analysis showed that CD163 and CCR1 had good diagnostic values for HF and NAFLD. Single-gene GSEA suggested that CD163 and CCR1 were mainly engaged in immune responses and inflammation. Experimental validation indicated unbalanced macrophage polarization in HF and NAFLD mouse models, and the expression of CD163 and CCR1 were significantly down-regulated. Conclusion: This study identified M2 polarization impairment characterized by decreased expression of CD163 and CCR1 as a common pathogenic pathway in NAFLD and HF. The downregulation of CD163 and CCR1 may reflect key pathological changes in the development and progression of NAFLD and HF, suggesting their potential as diagnostic and therapeutic targets.

Target genes associated with lipid and glucose metabolism in non-alcoholic fatty liver disease

Identification of Genes and Key Pathways Underlying the Pathophysiological Association Between Nonalcoholic Fatty Liver Disease and Atrial Fibrillation

Expressions of Key Regulatory Genes of the Lipid Metabolism in Livers During the Development of Rat Non-alcoholic Fatty Liver Disease

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

Potential roles of miR-152 in nonalcoholic fatty liver disease by the bioinformatic analysis

Identification of gene expression patterns in rat model of nonalcoholic fatty liver disease

Long Non-Coding Rna Profiling In A Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight Into Pathogenesis

Combined with multiplex and network analysis to reveal the key genes and mechanisms of nonalcoholic fatty liver disease

Identification of key target genes and pathway analysis in nonalcoholic fatty liver disease via integrated bioinformatics analysis

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Identification of Central Genes and Regulatory Pathways Associated with Hyperlipidemia in Rats

Transcriptomic profiling of hepatic tissues for drug metabolism genes in nonalcoholic fatty liver disease: A study of human and animals

Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease

A Study of the Changes of Hepatic Gene Expression in the Process of Nonalcoholic Fatty Liver Disease Development Using U230A Oligonucleotide Microarray

(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis related genes in non-alcoholic fatty liver disease.

Identification of common signature genes and pathways underlying the pathogenesis association between nonalcoholic fatty liver disease and heart failure

Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease.

MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease.

Gene-metabolite Network Analysis in Different Nonalcoholic Fatty Liver Disease Phenotypes

Identification of differentially expressed miRNAs and key genes involved in the progression of alcoholic fatty liver disease using rat models: DEGs in AFLD

Identification and validation of cuproptosis-related genes for diagnosis and therapy in nonalcoholic fatty liver disease